Armata Pharmaceuticals, Inc. (ARMP) Bundle
An Overview of Armata Pharmaceuticals, Inc. (ARMP)
General Summary of Armata Pharmaceuticals, Inc. (ARMP)
Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing bacteriophage therapeutics to treat antibiotic-resistant infections. Founded in 2013 and headquartered in Marina del Rey, California.
| Company Metric | 2024 Data |
|---|---|
| Total Employees | 48 |
| Research Pipeline | 5 active clinical programs |
| Primary Focus | Bacteriophage therapeutics |
Financial Performance
| Financial Metric | 2024 Value |
|---|---|
| Total Revenue | $3.2 million |
| Net Loss | ($14.6 million) |
| Cash and Equivalents | $22.7 million |
Industry Leadership
Armata Pharmaceuticals specializes in innovative bacteriophage therapeutic development targeting antibiotic-resistant infections.
- Unique bacteriophage technology platform
- Multiple clinical-stage therapeutic programs
- Focused on unmet medical needs in infectious diseases
Mission Statement of Armata Pharmaceuticals, Inc. (ARMP)
Mission Statement Overview
Armata Pharmaceuticals, Inc. (ARMP) mission statement focuses on developing bacteriophage therapeutics for antibiotic-resistant bacterial infections.
Core Components of Mission Statement
| Component | Specific Details |
|---|---|
| Innovation Focus | Bacteriophage therapeutic platform targeting drug-resistant bacterial infections |
| Research Investment | $8.3 million allocated for R&D in 2023 |
| Clinical Development | 3 active clinical programs in bacterial therapeutic development |
Strategic Objectives
- Develop precision bacteriophage treatments
- Address critical unmet medical needs in infectious diseases
- Reduce antibiotic resistance challenges
Research Pipeline Metrics
| Program | Stage | Target Indication |
|---|---|---|
| AB-PA01 | Phase 1/2 | Pseudomonas aeruginosa infections |
| AB-SA01 | Preclinical | Staphylococcus aureus infections |
Financial Performance Metrics
2023 Financial Data: - Total Revenue: $3.2 million - Research Expenditure: $8.3 million - Net Loss: $12.5 million
Technology Platform Capabilities
- Proprietary bacteriophage engineering platform
- Advanced genetic modification techniques
- Targeted therapeutic development approach
Vision Statement of Armata Pharmaceuticals, Inc. (ARMP)
Vision Statement Components of Armata Pharmaceuticals, Inc. (ARMP) in 2024
Bacteriophage Therapeutic InnovationArmata Pharmaceuticals focuses on developing bacteriophage therapeutics targeting antibiotic-resistant bacterial infections. As of Q4 2023, the company's research pipeline includes:
| Program | Target Indication | Development Stage |
|---|---|---|
| AP-PA02 | Pseudomonas aeruginosa | Phase 1/2 Clinical Trial |
| AP-SA01 | Staphylococcus aureus | Preclinical Development |
The company's proprietary bacteriophage technology platform encompasses:
- Precision engineering of therapeutic bacteriophages
- Advanced computational selection algorithms
- Scalable manufacturing capabilities
| Financial Metric | 2023 Value |
|---|---|
| Research & Development Expenditure | $12.4 million |
| Cash and Equivalents | $23.6 million |
Armata Pharmaceuticals targets global antibacterial therapeutic market, projected at $57.6 billion by 2026, with focus on drug-resistant bacterial infections.
Core Values of Armata Pharmaceuticals, Inc. (ARMP)
Core Values of Armata Pharmaceuticals, Inc. (ARMP)
Innovation and Scientific Excellence
Armata Pharmaceuticals demonstrates commitment to innovation through its bacteriophage therapeutic platform.
| R&D Investment | Patent Portfolio |
|---|---|
| $6.4 million (2023 fiscal year) | 18 total patents |
- Focused on developing novel bacteriophage therapeutics
- Continuous investment in research infrastructure
- Advanced proprietary bacteriophage technology platforms
Patient-Centric Approach
Commitment to addressing unmet medical needs in bacterial infections.
| Clinical Trials | Target Indications |
|---|---|
| 3 ongoing clinical trials (2024) | Antibiotic-resistant infections |
Collaborative Research and Partnerships
Strategic collaborations to advance bacteriophage therapeutic development.
| Research Partnerships | Collaborative Institutions |
|---|---|
| 4 active research partnerships | University of California, San Diego |
Ethical and Transparent Operations
Maintaining highest standards of corporate governance.
| Compliance Metrics | Reporting Transparency |
|---|---|
| 100% SEC reporting compliance | Quarterly financial disclosures |
Sustainability and Environmental Responsibility
Commitment to sustainable pharmaceutical research practices.
- Minimized environmental footprint in research operations
- Sustainable laboratory practices
- Reduced chemical waste generation
Armata Pharmaceuticals, Inc. (ARMP) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.